News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Daiichi Sankyo, Inc. Turns to Profit, Appoints New CEO, Joji Nakayama
May 12, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Daiichi Sankyo Co., Japan’s third- largest drugmaker, posted a full-year profit after a one-time charge in the previous period related to its Indian unit Ranbaxy Laboratories Ltd.
Twitter
LinkedIn
Facebook
Email
Print
People
Daiichi Sankyo
MORE ON THIS TOPIC
Collaboration
Novartis Sticks With Monte Rosa in Second Molecular Glue Deal Worth up to $5.7B
September 15, 2025
·
2 min read
·
Tristan Manalac
Europe
AstraZeneca Suspends $270M UK Commitment Months After Scrapping Vaccine Facility
September 15, 2025
·
2 min read
·
Tristan Manalac
Layoff Tracker
Merck To Cut 125 Employees as It Ends UK R&D Work
September 12, 2025
·
198 min read
·
BioSpace Editorial Staff
Patents
AbbVie Adds Four Years of Exclusivity to Rinvoq Franchise With Generics Settlement
September 12, 2025
·
2 min read
·
Tristan Manalac
